Cutaneous necrotizing vasculitis

International Journal of Dermatology

Volumn 35, Issue 7, 1996, Pages 457-474

  Lotti, Torello ^a   Comacchi, Claudio ^a   Ghersetich, Ilaria ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMINOCAPROIC ACID; ANTIHISTAMINIC AGENT; ANTIMALARIAL AGENT; CELL ADHESION MOLECULE; CORTICOSTEROID; DAPSONE; FIBRINOLYTIC AGENT; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY; NEUROPEPTIDE; NONSTEROID ANTIINFLAMMATORY AGENT; POTASSIUM IODIDE;

CLINICAL FEATURE; CREAM; DISEASE ASSOCIATION; FIBRINOLYSIS; HISTOPATHOLOGY; HUMAN; NECROTIZING ARTERITIS; PATHOGENESIS; REVIEW; SKIN DISEASE; TOPICAL DRUG ADMINISTRATION;

EID: 0030056379     PISSN: 00119059     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-4362.1996.tb01656.x     Document Type: Review

References (242)

1. Soter NA, Austen KF. Cutaneous necrotizing angiitis. In: Samter M, et al., eds. Immunological diseases. Boston: Little, Brown, 1978:993-1109.
2. Ekenstam E, Callen JP. Cutaneous leukocytoclastic vasculitis: clinical and laboratory features of 82 patients seen in private practice. Arch Dermatol 1984; 120:484-490.
3. Ryan TJ. Cutaneous vasculitis. In: Champion RH, Burton JL, Ebling FGH, eds. Textbook of dermatology. 5th Ed. Oxford: Blackwell Scientific, 1992:1893-1961.
4. Braun-Falco O, Plewig G, Wolff HH, et al. Dermatology. Berlin/Heidelberg: Springer-Verlag, 1991:620-623.
5. Jorizzo JL, Solomon AR, Zanolli MD, et al. Neutrophilic vascular reactions. J Am Acad Dermatol 1988; 19:983-1005.
6. Soter NA, Wolff SM. Necrotizing vasculitis. In: Fitzpatrick TB, Eisen AZ, Wolff K, et al., eds. Dermatology in general medicine. New York: McGraw-Hill, 1987: 1300-1312.
7. Soter NA, Mihm MC Jr, Gigli I, et al. Two distinct cellular patterns in cutaneous necrotizing angiitis. J Invest Dermatol 1976; 66:344-350.
8. Savel PH, Perroud AM, Klotz-Levy B, et al. Vasculite leucocytoclastique et lymphocytarie des petits vaisseaux cutanés. Ann Dermatol Venereol (Paris) 1982; 109: 503-512.
9. Ghersetich I, Comacchi C, Lotti T. Vasculiti necrotizzanti cutanee: caratterizzazione dell'infiltrato cellulare ed espressione di alcune molecole di adesione. Abstract Book "Incontri Colombiani della Riviera," Sanremo, 24-26 April 1992:103.
10. Ghersetich I, Lotti T, Campanile G, et al. Lymphocytes and accessory cells in the infiltrate of leukocytoclastic vasculitis. Abstract Book "SCUR Meet," Lyon, 17-19 September 1992:94.
11. Ghersetich I, Comacchi C, Lotti T. La vasculite cutanée nécrosante: l'infiltrat cellulaire et l'expression de quelques récepteurs de molécules d'adhesion. Nouv Dermatol 1992; 11:852-853.
12. Ghersetich I, Campanile G, Comacchi C, et al. Immunohistochemical and ultrastructural aspects of leukocytoclastic cutaneous necrotizing vasculitis (CNV). J Invest Dermatol 1993; 100:545. [Abstr]
13. Gherserich I, Campanile G, Comacchi C, et al. The cell-mediated pathway in the pathogenesis of the leukocytoclastic form of cutaneous necrotizing vasculitis. Abstract Book "Dermatology 2000," Vienna 18-21 May 1993:271.
14. Ghersetich I, Campanile G, Comacchi C, et al. Cutaneous necrotizing vasculitis: are there indeed two distinct histopathological entities? Abstract Book "14th Colloquium of the International Society of Dermopathology," Siena, 26 June-1 July 1993:86.
15. Campanile G, Ghersetich I, Comacchi C, et al. The cell-mediated pathway in the pathogenesis of cutaneous necrotizing vasculitis. Abstract Book "Third Congress of the European Academy of Dermatology and Venereology," Copenhagen, 26-30 September 1993:395.
16. Resnick AH, Esterly NB. Vasculitis in children. Int J Dermatol 1985; 24:139.
17. Lynch PJ. Vascular reactions. In: Schachner LA, Hansen RC, eds. Pediatric dermatology. New York: Churchill Livingstone, 1988:959-1014.
18. Habif TP. Clinical dermatology. St. Louis: CV Mosby, 1990:453-471.
19. Schifferli JA, Saurat JH, Woodley DT. Cutaneous vasculitis. In: Ruiz-Maldonado R, Parish LC, Beare JM, eds. Textbook of pediatric dermatology. Philadelphia: Grune & Stratton, 1989:654-661.
20. Sams WM Jr. Necrotizing vasculitis. J Am Acad Dermatol 1980; 3:1-13.
21. Campanile G, Lotti T. Clinical aspects of cutaneous necrotizing vasculitis. Int Angiol 1995; 14:151-161.
22. Chan LS, Cooper KD, Rasmussen JE. Koebnerization as a cutaneous manifestation of immune complex-mediated vasculitis. J Am Acad Dermatol 1990; 22:775-781.
23. Lever WF, Schaumburg-Lever G. Histopathology of the skin. Philadelphia: JB Lippincott, 1990:188-192.
24. McDuffie FC, Sams WM Jr, Maldonado JE, et al. Hypocomplementemia with cutaneous vasculitis and arthritis: possible immune complex syndrome. Mayo Clin Proc 1973; 48:340-348.
25. Sanchez NP, Winkelmann RK, Schroeter AL, et al. The clinical and histopathologic spectrums of urticarial vasculitis: study of forty cases. J Am Acad Dermatol 1982; 7:599-605.
26. Parish WE. Studies on vasculitis. Immunoglobulins, B1C, C-reactive protein, and bacterial antigens in cutaneous vasculitis lesions. Clin Allergy 1971; 1:97-109.
27. Gower RG. Small vessel vasculitis caused by hepatitis B virus immune complexes: small vessel vasculitis and HBsAG. J Allergy Clin Immunol 1978; 62:222.
28. Thorne EG, Gower R, Claman HN. Hepatitis B surface antigen and leukocytoclastic vasculitis. J Invest Dermatol 1977; 68:243-247.
29. Heart-Holmes M, Zahradka S, Baethge BA, et al. Leukocytoclastic vasculitis associated with hepatitis C. Am J Med 1991; 90:765-766.
30. Dan M, Yaniv R. Cholestatic hepatitis, cutaneous vasculitis and vascular deposits of immunoglobulin M and complement associated with hepatitis A virus infection. Am J Med 1990; 89:103-104.
31. Parish WE. Microbial antigens in vasculitis. In: Wolff K, Winkelman RK, eds. Vasculitis. London: Lloyd-Luke Medical Books, 1980:129.
32. Parish WE. Cutaneous vasculitis: the occurrence of complexes of bacterial antigens with antibody, and of abnormalities associated with chronic inflammation. In: Beutner EH, et al., eds. Immunopathology of the skin: labelled antibody studies. Chicago: Year Book, 1974:153.
33. Mosovich B, Biton A, Avinoach I. Vasculitis with cutaneous necrosis induced by oral contraceptive. Harefuah 1991; 120:451-453.
34. Patel A, Prussick R, Buchanan WW, et al. Serum sickness-like illness and leukocytoclastic vasculitis after intravenous streptokinase. J Am Acad Dermatol 1991; 24:652-653.
35. Parker CW. Drug allergy. In: Parker CW, ed. Clinical immunology. Philadelphia: WB Saunders, 1980:1219-1260.
36. Berman BA, Ross RN. Acute serum sickness. Cutis 1983; 32:420-422.
37. Vial T, Laine V, Delcombel M, et al. Vasculitis after anti-influenza vaccination. Report of 5 cases. Therapie 1990; 45:509-512.
38. Drago F, Arditi M, Rebora A. Tamoxifen and purpuric vasculitis. Ann Intern Med 1990; 112:965-966.
39. Hodge SJ, Caller JP, Ekenstom E. Cutaneous leukocytoclastic vasculitis: correlation of histopathological changes with clinical severity and course. J Cutan Pathol 1987; 14:279-284.
40. Lakhanpal S, Conn DL, Lie JT. Clinical and prognostic significance of vasculitis as an early manifestation of connective tissue disease syndrome. Ann Intern Med 1984; 101:743-748.
41. Estes D, Christian DL. The natural history of systemic lupus erythematosus by prospective analysis. Medicine 1971; 50:85-95.
42. Dubois EL, Wallace DJ. Clinical and laboratory manifestations of systemic lupus erythematosus. In: Wallace DJ, et al., eds. Lupus erythematosus. Philadelphia: Lea & Febiger, 1987:317-449.
43. Chevalier X, Belmatoug N, Kahn MF. Seronegative leukocytoclastic vasculitis preceding the onset of disseminated systemic lupus erythematosus. Rev Rhum Mal Osteoartic 1990; 57:779-783.
44. O'Loughlin S, Schroeter AL, Jordan RE. Chronic urticaria-like lesions in systemic lupus erythematosus. Arch Dermatol 1978; 114:879-883.
45. Christian CL, Sergent JJ. Vasculitis syndromes: clinical and experimental models. Am J Med 1976; 61:385-392.
46. Lawley TJ, Moutsopoulos HM, Katz SI, et al. Demonstration of circulating immune complexes in Sjögren's syndrome. J Immunol 1979; 123:1382-1387.
47. Moutsopoulos HM, Chused TM, Mann DL, et al. Sjögren's syndrome (sicca syndrome): current issues. Ann Intern Med 1980; 92:212-226.
48. Talal N, Moutsopoulos HM, Kassan SS. Sjögren syndrome. Clinical and immunological aspects. Berlin: Springer, 1987.
49. Gray RG, Poppo MJ. Necrotizing vasculitis as the initial manifestation of rheumatoid arthritis. J Rheumatol 1983; 10:326-328.
50. Nishikawa JA. Are leg ulcers in rheumatoid arthritis due to vasculitis? Eur J Rheum Inflam 1983; 6:288-290.
51. Jorizzo JL, Daniels JC. Dermatologic conditions reported in patients with rheumatoid arthritis. J Am Acad Dermatol 1983; 8:439-457.
52. Smith ML, Jorizzo JL, Semble E. Rheumatoid papules: lesions showing features of vasculitis and palisading granuloma. J Am Acad Dermatol 1989; 20:348-352.
53. Levinsky RJ, Lehner J, Circulating soluble immune complexes in recurrent oral ulceration and Behçet' syndrome. Clin Exp Immunol 1978; 32:193-198.
54. Valesini G, Picardo M, Pastare R, et al. Circulating immune complexes in Behçet's syndrome: purification, characterization and cross reactivity studies. Clin Exp Immunol 1981; 44:522-527.
55. Jorizzo J. Behçet's disease. An update based on the 1985 international conference in London. Arch Dermatol 1986; 122:556-558.
56. Waldenström J. Dysproteinemias. In: Fitzpatrick TB, Eisen AZ, Wolff K, et al, eds. Dermatology in general medicine. New York: McGraw-Hill, 1987:1650-1654.
57. Braun-Falco O, Plewig G, Wolff HH, et al. Dermatology. Berlin/Heidelberg: Springer-Verlag, 1991:877-878.
58. Boom BW, Brand A, Bouwes-Bavink JN, et al. Severe leukocytoclastic vasculitis of the skin in a patient with essential mixed cryoglobulinemia treated with high-dose gamma-globulins intravenously. Arch Dermatol 1988; 124:1550-1553.
59. Bronet JC, Clauvel JP, Danon F, et al. Biologic and clinical significance of cryoglobulinemia: a report of 86 cases. Am J Med 1974; 57:775-788.
60. Popp JW Jr, Dienstag JL, Wands JR, et al. .Essential mixed cryoglobulinemia without evidence for hepatitis B virus infection. Ann Intern Med 1980; 92:379-383.
61. Ely PH. The bowel bypass syndrome: a response to bacterial peptidoglycans. J Am Acad Dermatol 1980; 2: 473-487.
62. Dicken CH, Seehafter JR. Bowel bypass syndrome. Arch Dermatol 1979; 115:837-839.
63. Gilliam JN, Smiley JD. Cutaneous necrotizing vasculitis and related disorders. Ann Allergy 1976; 37:328-339.
64. Webb AK. Management problems of the adult with cystic fibrosis. Schweiz Med Wochenschr 1991; 121:110-114.
65. Soter NA, Nihm MC Jr, Colten HR. Cutaneous necrotizing venulitis in patients with cystic fibrosis. J Pediatr 1979; 95:197.
66. Weimer CE Jr, Sahn EE. Follicular accentuation of leukocytoclastic vasculitis in an HIV-seropositive man. Report of a case and review of the literature. J Am Acad Dermatol 1991; 24:898-902.
67. Cockerell CJ. Noninfectious inflammatory skin diseases in HIV-infected individuals. Dermatol Clin 1991; 9: 531-541.
68. Barlow RJ, Schulz EJ. Necrotizing folliculitis in AIDS-related complex. Br J Dermatol 1987; 116:581-584.
69. Kurzrock R, Cohen PR. Vasculitis and cancer. Clin Dermatol 1993; 11:175-187.
70. Greer JM, Lousley S, Edwards NL, et al. Vasculitis associated with malignancy. Medicine 1988; 67:220-229.
71. Nevin M, Armus S, Wolff M, et al. Cutaneous T-cell lymphoma in association with leukocytoclastic vasculitis. Int J Dermatol 1991; 30:443-444.
72. Kesseler ME, Slater DN. Cutaneous vasculitis: a presenting feature in Hodgkin's disease. J R Soc Med 1986; 79: 485-486.
73. Sams WM Jr, Harville DD, Winkelmann RK. Necrotizing vasculitis associated with lethal reticuloendothelial diseases. Br J Dermatol 1968; 80:555-560.
74. Kois JM, Sexton FM, Lookingbill DP. Cutaneous manifestations of multiple myeloma. Arch Dermatol 1991; 127:69-74.
75. Beylot J, Malou M, Doutre MS, et al. Leukocytoclastic vasculitis and malignant hematologic diseases (12 cases). Rev Med Interne 1989; 10:509-514.
76. Callen JP. Cutaneous leukocytoclastic vasculitis in a patient with an adenocarcinoma of the colon. J Rheumatol 1987; 14:386-389.
77. Lewis JE. Urticarial vasculitis occurring in association with visceral malignancy. Acta Derm Venereol (Stockh) 1990; 70:344-345.
78. Saulsbury FT. Henoch-Schönlein purpura. Pediatr Dermatol 1984; 1:195-201.
79. Palier AS. Disorders of the immune system. In: Schachner LA, Hansen RC. eds. Pediatric dermatology. New York: Churchill Livingstone, 1988:93-137.
80. Heng MCY. Henoch-Schönlein purpura. Br J Dermatol 1985; 112:235-240.
81. VanHale HM, Gibson LE, Schroeter AL. Henoch-Schönlein vasculitis: direct immunofluorescence study of uninvolved skin. J Am Acad Dermatol 1986; 15:665-670.
82. Stevenson JA, Leong LA, Cohen AH, et al. Henoch-Schönlein purpura. Simultaneous demonstration of IgA deposits in involved skin, intestine, and kidney. Arch Pathol 1982; 106:192-195.
83. Soter NA. Chronic urticaria as a manifestation of necrotizing venulitis. N Engl J Med 1977; 296:1440-1442.
84. Wanderer AA, Nuss DD, Thormey AD, et al. Urticarial leukocytoclastic vasculitis with cold urticaria: report of a case and review of the literature. Arch Dermatol 1983; 119:145-151.
85. Monroe EF. Urticarial vasculitis: an update review. J Am Acad Dermatol 1981; 5:88-95.
86. Gallen JP, Kalbfleisch S. Urticarial vasculitis: a report of nine cases and review of the literature. Br J Dermatol 1982; 107:87-94.
87. Scherer R. Urtikariavaskulitis. Hautarzt 1985; 36(Suppl 7):48-50.
88. Borradori L, Rybojad M, Puissant A, et al. Urticarial vasculitis associated with monoclonal IgM gammopathy: Schnitzler's syndrome. Br J Dermatol 1990; 123:113-118.
89. Grassegger A, Greil R, Feichtinger J, et al. Urticarial vasculitis as a symptom of Muckle-Wells syndrome? Hautarzt 1991; 42:116-119.
90. Cream JJ, Leven GM, Calnan CD. Erythema elevatum diutinum. Br J Dermatol 1971; 84:393-399.
91. Le Boit PE, Yen TSB, Wintroub B. The evolution of lesions in erythema elevatum diutinum. Am J Dermatopathol 1986; 8:392-402.
92. Wolff HH, Scherer R, Maciejewski W, et al. Erythema elevatum diutinum. II. Immunoelectromicroscopical study of leukocytoclastic vasculitis within the intracutaneous test reaction induced by streptococcal antigen. Arch Dermatol Res 1978; 261:17-26.
93. Feldacker M, Hines EA, Kierland RR. Livedo reticularis with summer ulcerations. Arch Dermatol Syphilol 1955; 72:31-37.
94. Marsch WC, Muckelmann R. Generalized racemose livedo with cerebrovascular lesions (Sneddon syndrome): an occlusive arteriolopathy due to proliferation and migration of medial smooth muscle cells. Br J Dermatol 1985; 112:703-708.
95. Braun-Falco O, Plewig G, Wolff HH, et al. Dermatology. Berlin: Springer-Verlag, 1991:637-638.
96. Diaz-Perez J, Winkelmann RK. Cutaneous periarteritis nodosa. Arch Dermatol 1974; 110:407-412.
97. Smoller BR, McNutt S, Contreras F. The natural history of vasculitis. Arch Dermatol 1990; 126:84-89.
98. Zax RH, Hodge SJ, Callen JP. Cutaneous leukocytoclastic vasculitis; serial histopathologic evaluation demonstrates the dynamic nature of the infiltrate. Arch Dermatol 1990; 126:69-72.
99. Gower RG, Sams WM Jr, Thorne EG, et al. Leukocytoclastic vasculitis: sequential appearance of immunoreactants and cellular changes in serial biopsies. J Invest Dermatol 1977; 69:477-484.
100. Dixon FJ, Vazquez JJ, Wiegle WO, et al. Pathogenesis of serum sickness. Arch Pathol Lab Med 1958; 65:18-28.
101. Mackel SE, Jordon RE. Leukocytoclastic vasculitis: a cutaneous expression of immune complex disease. Arch Dermatol 1982; 118:296-301.
102. Cream JJ, Bryceson ADM, Ryder G. Disappearance of immunoglobulin and complement from the Arthus reaction and its relevance to studies of vasculitis in man. Br J Dermatol 1971; 84:106-109.
103. Braverman IM, Yen A. Demonstration of immune complexes in spontaneous and histamine-induced lesions and in normal skin of patients with leukocytoclastic vasculitis. J Invest Dermatol 1975; 64:105-112.
104. Tosca N, Stratigos JD. Possible pathogenetic mechanisms in allergic cutaneous vasculitis. Int J Dermatol 1988; 27:291-296.
105. Yancey KB, Lawley TJ. Circulating immune complexes: their immunochemistry, biology and detection in selected dermatologic and systemic diseases. J Am Acad Dermatol 1984; 10:711-731.
106. Cochrane GG. Mediators of the Arthus and related reactions. Prog Allergy 1967; 11:1-35.
107. Claudy AL. Vascularities leucocytaires: nouvaux concepts physiopathologiques. Ann Dermatol Venereol 1990; 117:419-422.
108. Gimbrone MA, Brock AF, Schafer AI. Leukotriene B4 stimulates polymorphonuclear leukocyte adhesion to cultured vascular endothelial cells. J Clin Invest 1984; 74:1552-1555.
109. Hoover RL, Karnovsky MJ, Austen KF, et al. Leukotriene B4 action on endothelium mediates augmented neutrophil/endothelial adhesion. Proc Natl Acad Sci USA 1984; 81:2191-2193.
110. Zimmerman GA, Hill HR. Inflammatory mediators stimulate granulocyte adherence to cultured endothelial cells. Thromb Res 1984; 35:203-217.
111. Bevilacqua MP, Prober JS, Wheeler ME, et al. Interleukin-1 acts on cultured human vascular endothelium to increase adhesion of polymorphonuclear leukocytes, monocytes, and related leukocyte cell lines. J Clin Invest 1985; 76:2003-2011.
112. Gamble JR, Harlan JM, Klebanoff SJ. Stimulation of the adhesion of neutrophils to umbilical vein endothelium by human recombinant tumor necrosis factor. Proc Natl Acad Sci USA 1985; 82:8667-8671.
113. Pohlman TH, Stanness KA, Beatty PG, et al. An endothelial cell surface factor(s) induced in vitro by LPS, IL-1, and TNF alfa increased neutrophil adherence by a CDw18-dependent mechanism. J Immunol 1986; 136: 4548-4553.
114. Lotti T, Campanile G, Ghersetich I, et al. Endothelium-blood cells interactions in thrombosis. In: Neri Serneri GG, Gensini GF, Abbate R, eds. Thrombosis: an update. Scientific Press, 1992; 669-693.
115. Bevilacqua MP, Stengelin S, Gimbrone MA, et al. ELAM-1: an inducible receptor for neutrophils related to complement regulatory proteins and lectins. Science 1989; 243: 1160-1164.
116. Bevilacqua MP, Pober JS, Mendrick DL, et al. Identification of an inducible endothelial-leukocyte adhesion molecule. Proc Natl Acad Sci USA 1987; 84:9238-9242.
117. Picker LJ, Kishimoto TK, Smith CW, et al. ELAM-1 is an adhesion molecule for skin-homing T cells. Nature 1991; 349:737-738.
118. Leeuwenberg JFM, Jeunhomme TMAA, Burman WA. Role of ELAM-1 in adhesion of monocytes to activated human endothelial cells. Scand J Immunol 1992; 35: 335-341.
119. Larsen E, Celi A, Gilbert GE, et al. PADGEM protein: a receptor that mediates the interaction of activated platelets with neutrophils and monocytes. Cell 1989; 59:305-312.
120. Johnston GI, Cook RG, McEver RP. Cloning of GMP-140, a granule membrane protein of platelets and endothelium: sequence similarity to proteins involved in cell adhesion and inflammation. Cell 1989; 56:1033-1044.
121. Jutila MA, Rott L, Berg EL, et al. Function and regulation of the neutrophil Mel-14 antigen in vivo: comparison with LFA-1 and Mac-1. J Immunol 1989; 143:3318-3324.
122. Carlos TM, Harlan JM. Membrane proteins involved in phagocyte adherence to endothelium. Immunol Rev 1990; 114:5-28.
123. Geng JG, Bevilacqua MS, Moore KL, et al. Rapid neutrophil adhesion to activated endothelium mediated by GMP-140. Nature 1990; 343:757-760.
124. Osborne L. Leukocyte adhesion to endothelium in inflammation. Cell 1990; 62:3-6.
125. McEver RP. Selectine: novel receptors that mediates leukocyte adhesion during inflammation. Thromb Haemost 1991; 65:223-228.
126. Covnacoff JB, Hebert LA, Smead WL, et al. Primate erythrocyte-immune complex-clearing mechanism. J Clin Invest 1983; 71:236-247.
127. Ryan TJ. The epidermis and its blood supply in varicose disorders of the leg. Trans St Johns Hosp Dermatol Soc (London) 1969; 55:51-59.
128. Cotran RS. Delayed and prolonged leakage in inflammation. III: Immediate and delayed reactions in skeletal muscle. Exp Mol Pathol 1967; 6:143-155.
129. Hensen PM. Interaction of cells with immune complexes: adherence, release of constituents and tissue injury. J Exp Med 1971; 134:114-135.
130. Isaacson S, Linele F, Maller H, et al. Coagulation and fibrinolysis in chronic panniculitis. Acta Dermatol Venereol (Stockh) 1970; 50:213.
131. Parish WE. Cutaneous vasculitis: antigen-antibody complexes and prolonged fibrinolysis. Proc R Soc Med 1972; 65:276.
132. Lotti T, Dindelli A, Barontini A, et al. Fibrin deposits and fibrinolytic activity in certain dermatoses with immunological pathogenesis. Ital Gen Rev Dermatol 1979; 2-3:189.
133. Fabbri P, Lotti T, Dindelli A, et al. Studio della fibrinolisi tissutale e plasmatica nella vasculite necrotizzante cutanea. Ann Ital Dermatol Clin Sper 1981; 35:347-354.
134. Bianchini G, Lotti T, Fabbri P. Fibrin deposits and fibrinolytic activity in Schönlein-Henoch syndrome. Int J Dermatol 1983; 22:103-106.
135. Ryan TJ. Inflammation, fibrin and fibrinolysis. In: The physiology and pathophysiology of the skin. Vol 2. London/New York: Academic Press, 1973.
136. Lotti T, Fabbri P, Panconesi E. Cutaneous fibrinolytic activity in urticaria and vasculitis. In: Champion RHEA, ed. The urticarias. Edinburgh: Churchill-Livingstone 1985:161-164.
137. Panconesi E, Lotti T. Fibrinolysis and fibrinolytic drugs. In: Greaves MW, et al, eds. Handbook of experimental pharmacology. Berlin: Springer-Verlag 1989: 279-300.
138. Jordan JM, Bates AN, Pizzo SV. Defective release of tissue plasminogen activator in systemic and cutaneous vasculitis. Am J Med 1987; 82:397-400.
139. Teofoli P, Lotti T. Cytokines, fibrinolysis and vasculitis. Int Angiol. (Submitted)
140. Kahaleh B, Matucci-Cerinic M. Endothelial injury and its implications. In: Neri Serneri GG, Gensini GF, Abbate R, eds. Thrombosis: an update. Scientific Press, 1992: 649-658.
141. Pober JS. Cytokine-mediated activation of vascular endothelium. Physiology and pathology. Am J Pathol 1988; 133:426-433.
142. Mantovani A, Dejana E. Cytokines as communication signals between leukocytes and endothelial cells. Immunol Today 1989; 10:370-375.
143. Pober JS, Cotran RS. Cytokines and endothelial cell biology. Physiol Rev 1990; 70:27-51.
144. Prydz H, Pettersen KS. Synthesis of thromboplastin (tissue factor) by endothelial cells. Haemostasis 1988; 18: 215-223.
145. Nemerson Y. Tissue factors and hemostasis. Blood 1988; 71:1-8.
146. Rosemberg RD, Rosemberg JS. Natural anticoagulant mechanism. J Clin Invest 1984; 74:1-5.
147. Stern DM, Brett J, Harris K, et al. Participation of endothelial cells in the protein-C-protein-S anticoagulant pathway: the synthesis and release of protein-S. J Cell Biol 1986; 102:1971-1978.
148. Moncada S, Vane JR. Arachidonic acid metabolites and the interactions between platelets and blood-vessel walls. N Engl J Med 1979; 300:1142-1147.
149. Lieberman GE, Lewis GP, Peters TJ. A membrane-bound enzyme in rabbit aorta capable on inhibiting adenosine-diphosphate-induced platelet aggregation. Lancet 1977; 2:330-332.
150. Romagnani S, Caligaris Cappio F. Immunologia clinica e allergologica. Torino: UTET, 1991:51-101.
151. Bevilacqua MP, Pober JS, Majeau RS, et al. Interleukin-1 (IL-1) induces biosynthesis and cell surface expression of procoagulant activity in human vascular endothelial cells. J Exp Med 1984; 160:618-623.
152. Rossi V, Breviario F, Ghezzi P, et al. Prostacyclin synthesis induced in vascular cells by interleukin-1. Science 1985; 229:174-176.
153. Nachman RL, Hajjar KA, Silverstein RL, et al. Interleukin 1 induces endothelial cell synthesis of plasminogen activator inhibitor. J Exp Med 1986; 163:1595-1600.
154. Pober JS, Lapierre LA, Stolpen AH, et al. Activation of cultured human endothelial cells by recombinant lymphotoxin: comparison with tumor necrosis factor and interleukin 1 species. J Immunol 1987; 138:3319-3324.
155. Wakefield PE, James WD, Samlaska CP, et al. Tumor necrosis factor. J Am Acad Dermatol 1991; 24:675-675.
156. Nawroth PP, Stern DM. Modulation of endothelial cell hemostatic properties by TNF. J Exp Med 1986; 163: 740-745.
157. Endo H, Akahoshi T, Kashiwazaki S. Additive effects of IL-1 and TNF on induction of prostacyclin synthesis in human vascular endothelial cells. Biochem Biophys Res Commun 1988; 156:1007-1014.
158. Jirik FR, Podor TJ, Hirano T, et al. Bacterial lipopolysaccharide and inflammatory mediators augment IL-6 secretion by human endothelial cells. J Immunol 1989; 142:144-147.
159. Stricter RM, Wiggins R, Phan SH, et al. Monocyte chemotactic protein gene expression by cytokine-treated human fibroblasts and endothelial cells. Biochem Biophys Res Commun 1989; 162:694-699.
160. Libby P, Ordovas JM, Auger KR, et al. Endotoxin and tumor necrosis factor induce interleukin-1 gene expression in adult human vascular endothelial cells. Am J Pathol 1986; 124:179-185.
161. Sieff CA, Tsai S, Faller DV. Interleukin 1, tumor necrosis factor and the production of colony-stimulating factors by cultured mesenchymal cells. Blood 1988; 72: 1316-1323.
162. Hajjar KA, Hajjar DP, Silverstein RL, et al. Tumor necrosis factor-mediated release of platelet-derived growth factor from cultured endothelial cells. J Exp Med 1987; 166:235-245.
163. Ripoche J, Mitchell JA, Erdei A, et al. Interferon-gamma induces synthesis of complement alternative pathway proteins by human endothelial cells in culture. J Exp Med 1988; 168:1917-1922.
164. Masuyama J, Minato N, Kano S. Mechanisms of lymphocyte adhesion to human vascular endothelial cells in culture. T lymphocyte adhesion to endothelial cells through endothelial HLA-DR antigens induced by gamma interferon. J Clin Invest 1986; 77:1596-1605.
165. Fauci AS, Haynes BF. The spectrum of vasculitis: clinical, pathologic and therapeutic considerations. Ann Intern Med 1978; 80:660-676.
166. Tosca A, Hatzis J, Kyriakis K, et al. Delayed hypersensitivity and differences of histologic pattern in allergic cutaneous vasculitis. Angiology 1988; 39:360-364.
167. Lotti T, Ghersetich I, Comacchi C, et al. Immunophenotype and ultrastructure of infiltrate in the lymphocytic form of "cutaneous necrotizing vasculitis." Abstract Book "EADV 2nd Congress," Athens, Greece, 10-13, October 1991:204.
168. Campanile G, Ghersetich I, Comacchi C, et al. Studio immunoistochimico e ultrastrutturale dell'infiltrato nelle vasculiti necrotizzanti cutanee linfocitarie. G Ital Dermatol Venereol 1992; 127:337-341.
169. Marchesi VT, Gowans JL. The migration of lymphocytes through the endothelium of venules in lymph node. Proc R Soc Lond 1964; 159:283-292.
170. Cagnoni ML, Ghersetich I, Lotti T. Cell adhesion molecules in inflammatory and neoplastic skin diseases. J Eur Acad Dermatol Venereol 1993; 2:94-112.
171. Makgoba MW, Sanders ME, Ginter Luce GE, et al. Functional evidence that intercellular adhesion molecule-1 (ICAM-1) is a ligand for LFA-1-dependent adhesion in T cell-mediated cytotoxicity. Eur J Immunol 1988; 18:637-640.
172. Staunton DE, Dustin ML, Springer TA. Function cloning of ICAM-2, a cell adhesion ligand for LFA-1 homologous to ICAM-1. Nature 1989; 339:61-64.
173. Carter SB. Principles of cell motility: the direction of cell movement and cancer invasion. Nature 1965; 208: 1183-1187.
174. Murphy GF. Allograft rejection and the cutaneous immune response. Presented at the annual meeting of the American Society of Dermatopathology; March 9, 1986, New Orleans, LA.
175. Clayton R, Haffenden G. An immunofluorescence study of pityriasis lichenoides. Br J Dermatol 1978; 99: 491-493.
176. Mullick FG, McAllister HA Jr, Wagner BM, et al. Drug-related vasculitis. Hum Pathol 1979; 10:313-325.
177. Katayama I, Masuzawa M, Nishioka K, et al. Anticardiolipin antibody in Henoch-Schönlein purpura and related vascular disorders. Arch Dermatol Res 1989; 281:296-298.
178. Harris EN, Gharavi AE, Boei ML, et al. Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus. Lancet 1983; ii:1211-1214.
179. Koike T, Sueishi M, Funaki H, et al. Antiphospholipid antibodies and biological false positive serological test for syphilis in patients with systemic lupus erythematosus. Clin Exp Immunol 1984; 56:193-199.
180. Franptor G, Cameron JS. Purified antiphospholipid antibody from lupus nephritis patients enhances thromboxane (TxB2) production by activated platelets. Abstract Book "3rd International Symposium on Antiphospholipid Antibody and Thrombosis," 1988.
181. Carreras LO, Defreyn G, Machine SJ, et al. Arterial thrombosis, intrauterine death and lupus anticoagulant. Detection of immunoglobulin interfering with prostacyclin production. Lancet 1981; i:244-246.
182. Katz AM, Rosenthal D, Sauder DN. Cell adhesion molecules. Structure, function, and implication in a variety of cutaneous and other pathologic conditions. Int J Dermatol 1991; 30:153-160.
183. Fleming S. Cellular functions of adhesion molecules. J Pathol 1990; 161:189-190.
184. Lotti T, Ghersetich I, Panconesi E. Le porpore. Dermotime 1991; 3:13-20.
185. Ghersetich I, Romagnoli P, Comacchi C, et al. The infiltrate and the adhesion molecule receptors in Schamberg disease. An immunohistochemical and ultrastructural study. J Invest Dermatol 1992; 98:616.
186. Ghersetich I, Lotti T, Bacci S, et al. The cell infiltrate in progressive pigmented purpura (Schamberg's disease): immunophenotype, adhesion receptors, intercellular relations. Int J Dermatol 1995; 34:846-850.
187. Teofoli P, Ghersetich I, Comacchi C, et al. Cell adhesion molecules in alopecia areata. Abstract Book "18 World Congress of Dermatology," New York, June 1992; 229a.
188. Teofoli P, Ghersetich I, Benci M, et al. Immunophenotypical and ultrastructural peribulbar infiltrate of adhesion molecule expression in alopecia areata in different clinical phases. J Invest Dermatol 1992; 98:599.
189. Ghersetich I, Lotti T. Cellular steps in the pathogenesis of cutaneous necrotizing vasculitis. Int Angiol 1995; 14: 107-112.
190. Cagnoni ML, Ghersetich I, Comacchi C, et al. Effects of treatment with topical calcipotriol on the expression of some cell adhesion molecules in psoriasis. Abstract Book "4th European Symposium on Psoriasis." Triest 16-19, September 1993:39.
191. Hynes RO. Integrins: a family of cell surface receptors. Cell 1978; 48:549-554.
192. Shimizu Y, Van Seventer GA, Horgan KJ, et al. Regulated expression and binding of three VLA (beta 1) integrin receptors on T cells. Nature 1990; 345:250-253.
193. Springer TA, Dustin ML, Kishimoto TK, et al. The lymphocyte function associated LFA-1, CD2, and LFA-3 molecules: cell adhesion receptors of the immune system. Ann Rev Immunol 1987; 5:223-252.
194. Springer TA. Adhesion receptors of the immune system. Nature 1990; 346:425-433.
195. de Fourgerolles AR, Springer TA. Intercellular adhesion molecule-3, a third adhesion counter-receptor for lymphocyte function associated molecule-1 on resting lymphocytes. J Exp Med 1992; 175:185-190.
196. Damle NK, Aruffo A. Vascular cell adhesion molecule 1 induces T-cell antigen receptor-dependent activation of CD4+ T lymphocytes. Proc Natl Acad Sci USA 1991; 88:6403-6407.
197. Volk T, Geiger B. A-CAM a 135kd receptor of intercellular adherens junctions: II. Antibody-mediated modulation of junction formation. J Cell Biol 1986; 103:1451-1464.
198. Nagafuchi A, Takaichi M. Transmembrane control of cadherin-mediated cell adhesion: a 94kd protein functionally associated with a specific region of the cytoplasmatic domain of E-cadherin. Cell Regul 1989; 1:37-44.
199. Phillips ML, Nudelman E, Gaeta FC, et al. ELAM-1 mediates cell adhesion by recognition of a carbohydrate ligand, sialyl-lex. Science 1990; 250:1130-1132.
200. Siegelman MH, van de Rjin M, Wissman IL. Mouse lymph node homing receptor for neutrophils relate to complement regulatory proteins and lectins. Science 1989; 243:1165-1172.
201. Albeda SM, Oliver PD, Romer LH, et al. EndoCAM: a novel endothelial cell-cell adhesion molecule. J Cell Biol 1990; 110:1227-1237.
202. Plow EF, Edgington TS. An alternative pathway for fibrinolysis. The cleavage of fibrinogen by leukocyte proteases at physiologic pH. J Clin Invest 1975; 56:30-33.
203. Collen D. On the regulation and control of fibrinolysis. Thromb Haemost 1980; 43:77-89.
204. Lotti T, Dindelli A, Fabbri P. Cutaneous fibrinolysis: a modified method of autohistographic identification of plasminogen activators in tissue. Technical note. Ital Gen Rev Dermatol 1980; 17:157-160.
205. Lotti T, Brunetti L, Casigliani R, et al. A new technique for detecting inhibitors of fibrinolysis in skin section. Technical note. Ital Gen Rev Dermatol 1983; 20: 105-109.
206. Dano K, Andreasen A, Grondahl-Hansen J, et al. Plasminogen activators, tissue degradation and cancer. Adv Cancer Res 1985; 1:139-265.
207. Robbins KC, Summaria L. The structure of human plasminogen. Methods Enzymol 1970; 19:184-199.
208. Loskutoff DJ, von Mourik JA, Erickson LA, et al. Detection of an unusually stable fibrinolytic inhibitor produced by bovine endothelial cells. Proc Natl Acad Sci USA 1983; 80:2956-2960.
209. Scheider AB, Kaplan AP, Austen KF. Inhibition of C1 INH of Hageman factor fragment activation of coagulation, fibrinolysis, and kinin generation. J Clin Invest 1973; 52:1402-1405.
210. Sipka S, Szilagyi T. Effect of lymphokines on fibrinolysis and kinin generation in human plasma. Acta Allergol 1977; 32:139-141.
211. Sipka S, Szilagyi T. Mechanism responsible for increased vascular permeability, fibrin deposits and chemotaxis in delayed hypersensitivity reactions. Br J Dermatol 1977; 97:469-473.
212. van Hinsbergh VMW, Kooistra T, van den Berg EA, et al. Tumor necrosis factor increases the production of plasminogen activator inhibitor in human endothelial cells in vitro and in rats in vivo. Blood 1988; 72:1467-1473.
213. Wikner NE, Elder JT, Persichitte KA, et al. Transforming growth factor-beta modulates plasminogen activator activity and plasminogen activator inhibitor type-1 expression in human keratinocytes in vitro. J Invest Dermatol 1990; 95:610-612.
214. Prue H, Burgess DR, Vitti GF, et al. Interleukin-4 stimulates human monocytes to produce tissue-type plasminogen activator. Blood 1989; 74:1222-1225.
215. Hautmann G, Lotti T. The role of regulatory peptides in the pathogenesis of cutaneous necrotizing vasculitis. Int Angiol 1995; 14:138-150.
216. Pincelli C, Fantini F. Neuropeptidi e cute. Dermo-time 1989; 3:9-11.
217. Brain SD, Tippins JR, Morris HR. Potent vasodilator activity of CGRP in human skin. J Invest Dermatol 1986; 87:533-536.
218. Cappugi P, Tsampau D, Lotti T. Substance P provokes cutaneous erythema and edema also through a histamine-independent pathway. Int J Dermatol 1992; 31: 85-88.
219. Bröker B, Lydyard PM, Emmrich F. The role of gamma/delta T cells in the normal and disordered immune system. Klin Wochenschr 1990; 68:489-494.
220. Alaibac M. Gamma/delta T lymphocytes: relevance of the current studies to dermatology. Int J Dermatol 1992; 31:157-159.
221. Comacchi C, Ghersetich I, Lotti T. Una cellula emergente in dermatologia: il linfocita T gamma/delta. G Ital Dermatol Venereol 1993; 128:133-140.
222. Campanile G, Comacchi C, Ghersetich I, et al. Gamma/delta TCR lymphocytes in cutaneous necrotizing vasculitis. Int Angiol 1995; 14:119-124.
223. Groh V, Porcelli S, Fabbi M, et al. Human lymphocytes bearing T-cell receptors gamma/delta are phenotypically diverse and evenly distributed throughout the lymphoid system. J Exp Med 1989; 169:1277-1294.
224. Janeway CA, Jones B, Hayday A. Specifity and function of T cell hearing gamma/delta receptors. Immunol Today 1988; 9:73-75.
225. Born WK, Happ MP, Dallas A, et al. Recognition of heat shock proteins and gamma/delta cell function. Immunol today 1990; 11:40-43.
226. Holoshitz J, Koning F, Coligan JE, et al. Isolation of CD4-, CD8-mycobacteria-reactive T lymphocyte clones from rheumatoid arthritis synovial fluid. Nature 1989; 339:226-229.
227. Ghersetich I, Campanile G, Comacchi C, et al. T lymphocytes bearing gamma/delta receptors: a clue to the etiology of cutaneous necrotizing vasculitis? Abstract Book "XII Convegno di Immunopatologia Cutanea." Geneva, 9-10 October 1992:12.
228. Ghersetich I, Campanile G, Comacchi C, et al. Gamma/delta TCR lymphocytes in cutaneous necrotizing vasculitis (CNV): a clue to the infective etiology. J Invest Dermatol 1993; 100:465.
229. Comacchi C, Ghersetich I, Campanile G, et al. Studio dei linfociti T gamma/delta nella vasculite cutanea necrotizzante leucocitoclasica. Abstract Book "68° Congreso Nazionale della Società Italiana di Dermatologia e Venereologia." Pisa, 23-26 June 1993:129.
230. Ghersetich I, Jorizzo JL, Lotti T. Working classification of vasculitis. Int Angiol 1995; 14:101-106.
231. Alexander EL, Arnett FC, Provost TT, et al. Sjögren's syndrome: association of anti-Ro (SSA) antibodies with vasculitis, hematologic abnormalities, and serologic hyperreactivity. Ann Intern Med 1983; 98:155-159.
232. Molina R, Provost TT, Alexander EL. Two types of inflammatory vascular disease in Sjögren syndrome. Arthritis Rheum 1985; 28:1251-1258.
233. Sanchez NP, Van Hale HM, Su WPD. Clinical and histopathological spectrum of necrotizing vasculitis. Arch Dermatol 1985; 121:220-224.
234. Burge S. The management of cutaneous vasculitis. In: Panconesi E, ed. Dermatology in Europe. Oxford: Blackwell Science, 1991:328-330.
235. Lotti T. The management of systemic complications of vasculitis. In: Panconesi E, ed. Dermatology in Europe. Oxford: Blackwell Science, 1991:330-332.
236. Mathieson PW, Cobbold SP, Hale CG, et al. Monoclonal-antibody therapy in systemic vasculitis. N Engl J Med 1990; 323:250-254.
237. Ryan TJ. Microvascular injury. Maj Probl Dermatol 1976; 7:373-405.
238. Katz SI. Erythema elevatum diutinum. Skin and systemic manifestations, immunologic studies and successful treatment with dapsone. Medicine 1977; 56:443-452.
239. Van Vroonhoven TJMV, Van Zijl J, Muller H. Low dose subcutaneous heparin versus oral anticoagulants. Lancet 1974; i:375-384.
240. Lotti T, Celasco G, Tsampau D, et al. Mesoglycan treatment restores defective fibrinolytic potential in cutaneous necrotizing venulitis. Int J Dermatol 1993; 32:368-371.
241. Isseroff SW, Whiting DA. Low molecular weight dextran in the treatment of livedo reticularis with ulceration. Br J Dermatol 1971; 85:26-29.
242. Haustein UF. Purpura hyperfibrinolytica als pathogenetisches [Prinzip hemorrhagischen Miescher.] Dermatol Monatsschrift 1969; 155:771-778.